Search results
(A) Trials of 5 years of tamoxifen (n=10 645; ∼80% complied). (B) ATLAS trial of 10 years vs 5 years of tamoxifen (n=6846; ∼80% difference in tamoxifen use ). (C) Hypothetical trial of 10 years of tamoxifen vs none (with ∼80% compliance). Two-sided p values in this table relate to particular time periods; values elsewhere combine all time ...
- Tamoxifen - StatPearls - NCBI Bookshelf - National Center for ...
Tamoxifen is a selective estrogen receptor modulator (SERM)...
- Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a ...
Taking tamoxifen for the recommended 5 years reduces the...
- Tamoxifen - StatPearls - NCBI Bookshelf - National Center for ...
10 kwi 2023 · Tamoxifen is a selective estrogen receptor modulator (SERM) medication used to treat breast cancer in men and women and as a prophylactic agent against breast cancer in women.
9 mar 2013 · Methods: In the worldwide Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial, 12,894 women with early breast cancer who had completed 5 years of treatment with tamoxifen were randomly allocated to continue tamoxifen to 10 years or stop at 5 years (open control).
Tamoxifen, a cornerstone in the adjuvant treatment of estrogen receptor-positive breast cancer, significantly reduces breast cancer recurrence and breast cancer mortality; however, its standard adjuvant dose of 20 mg daily presents challenges due to ...
Here, we assess the relationship between early reported side effects and incidence of breast cancer in women randomised to tamoxifen for cancer prevention in the International Breast Intervention Study (IBIS)–I trial.
12 paź 2018 · An extended 10 years of endocrine treatment yields a DFS benefit for patients with early breast cancer; (AI and/or TAM) 5y - AI 5y treatment is the optimal choice. ER+ and/or PR+, postmenopausal and lymph node-positive patients are the most suitable groups. Electronic supplementary material.
1 maj 2011 · Taking tamoxifen for the recommended 5 years reduces the risk of recurrence or contralateral breast cancer 15 years after starting treatment. It also lowers the risk of CV disease and death as a result of a CV event, particularly among those age 50 to 59 years.
